StockData
ELI LILLY & Co logo

ELI LILLY & Co

LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3025% above fair value
$1410.99−6.55 (-0.46%)

Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%

Eli Lilly Cyramza (ramucirumab) by Quarter

Cyramza (ramucirumab) — Worldwide revenue ($M) [legacy separate disclosure] ($M)

QuarterlyAnnual

Eli Lilly Cyramza (ramucirumab): $259M in Q4 2024, up 2.0% from a year earlier. No newer figure appears in the documents we track.

Latest, Q4 2024
259
Period ended Dec 31, 2024
Change on a year earlier
+2.0%
254 in Q4 2023
History
32 quarters
Since Q1 2017
Sources
28
Documents cited below

Where the Q4 2024 figure comes from

Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)

Source: Form 10-K FY2024 (filed 2025-02-19) ↗

Reported in Form 10-Q / 10-K Note 2 & MD&A (legacy separate product disclosure prior to FY2025 reorganization).

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCyramza (ramucirumab) — Worldwide revenue ($M) [legacy separate disclosure] ($M)Year on yearSource
Q4 2024Dec 31, 2024259+2.0%Form 10-K FY2024 (filed 2025-02-19) ↗
Q3 2024Sep 30, 2024236+5.3%Form 10-Q (filed 2024-10-30) ↗
Q2 2024Jun 30, 2024249-4.4%Form 10-Q (filed 2024-08-08) ↗
Q1 2024Mar 31, 2024230-2.9%Form 10-Q (filed 2024-04-30) ↗
Q4 2023Dec 31, 2023254-8.7%Earnings Release (Form 8-K FY2023Q4 EX-99.1) (filed 2024-02-06) ↗
Q3 2023Sep 30, 2023224-3.4%Form 10-Q (filed 2024-10-30) ↗
Q2 2023Jun 30, 2023260+12.5%Form 10-Q (filed 2024-08-08) ↗
Q1 2023Mar 31, 2023237+2.8%Form 10-Q (filed 2024-04-30) ↗
Q4 2022Dec 31, 2022278+2.7%Earnings Release (Form 8-K FY2022Q4 EX-99.1) (filed 2023-02-02) ↗
Q3 2022Sep 30, 2022232-8.4%Form 10-Q (filed 2023-11-02) ↗
Q2 2022Jun 30, 2022231-13.9%Form 10-Q (filed 2023-08-08) ↗
Q1 2022Mar 31, 2022230-4.2%Form 10-Q (filed 2023-04-27) ↗
Q4 2021Dec 31, 2021270-4.9%Earnings Release (Form 8-K FY2021Q4 EX-99.1) (filed 2022-02-03) ↗
Q3 2021Sep 30, 2021253+0.3%Form 10-Q (filed 2022-11-01) ↗
Q2 2021Jun 30, 2021269+4.7%Form 10-Q (filed 2022-08-04) ↗
Q1 2021Mar 31, 2021241+0.6%Form 10-Q (filed 2022-04-29) ↗

Breakdown

What makes up cyramza (ramucirumab)

Cite this data

StockData. (2026). Eli Lilly Cyramza (ramucirumab) ($M), quarterly Q1 2017–Q4 2024 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-cyramza-ww

See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.